NEW YORK, July 14, 2008
Nephros Exhibiting at Maryland ASHE Conference
July 20-23, 2008
NEW YORK, June 5, 2008
Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
NEW YORK, June 2, 2008
Nephros exhibiting at Denver, Colorado APIC Conference
June 15-19, 2008
NEW YORK, May 10, 2008
Nephros to Exhibit at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
NEW YORK, October 16, 2007
Nephros Initiates Pivotal U.S. Trial for OLpur™ H2H™ Hemodiafiltration Module and OLpur™ MD 220 Hemodiafilter
NEW YORK, October 3, 2007
Nephros Receives Non-Compliance Notification from Amex
NEW YORK, September 25, 2007
Nephros Raises $12.7 Million in New Financing
NEW YORK, August 13, 2007
Nephros Reports Second Quarter 2007 Financial Results
Revenues Increase 15%, Net Loss is Reduced
NEW YORK, August 7, 2007
Nephros Discloses Nonpayment of Installment under the Lancer Settlement Agreement in Current Report on Form 8-K
NEW YORK, July 20, 2007
Nephros Names New Independent Auditing Firm
NEW YORK, May 23, 2007
Nephros Reports Departure of Director
NEW YORK, May 16, 2007
Nephros to Initiate U.S. Clinical Trials
NEW YORK, May 15, 2007
Nephros Reports First Quarter 2007 Financial Results
Revenues Increase 70%, Net Loss is Reduced
NEW YORK, May 3, 2007
Nephros Provides Information Regarding Auditor's Going Concern Report and Fiscal 2006 Results
NEW YORK, May 1, 2007
Nephros Reports Departure of Director
NEW YORK, March 1, 2007
Nephros Completes Informational Request from the FDA on Investigational Device Exemption Application
Nephros MD and H2H Technologies Clinical Trials Expected to Commence in March 2007
NEW YORK, January 29, 2007
Nephros Receives Conditional Approval from the FDA of Investigational Device Exemption Application
Nephros MD and H2H Technologies Targeted to Begin Clinical Trials in First Quarter 2007
NEW YORK, December 6, 2006
Italian Clinical Study Demonstrates Nephros’ Mid-Dilution HDF Therapy As Optimal Treatment for Patients with Limited Vascular Access
NEW YORK, November 20, 2006
American Stock Exchange Will Continue Nephros’s Listing
NEW YORK, November 15, 2006
Nephros Reports Third Quarter 2006 Financial Results
NEW YORK, October 23, 2006
Multi-Center Study Concludes Nephros Mid-Dilution Hemodiafiltration Therapy Achieves Higher Clearance of Low Molecular Weight Proteins
Study Abstract Selected by Peer-Review Experts for Presentation
at American Society of Nephrology (ASN) Congress
NEW YORK, October 5, 2006
Nephros Announces Positive Results of Clinical Study for Olpur MD190 Mid-Dilution Hemodiafiltration Filter
Study Findings to be Presented at October Nephrology Congress in Madrid
NEW YORK, October 4, 2006
Nephros Selected for Development of Dual Stage Ultra Reliable Portable Personal Water Filtration by U.S. Marine Corps ATD
$1 Million Department of Defense Appropriation Approved
NEW YORK, August 22, 2006
Nephros Announces Restatement of Financial Statements
NEW YORK, August 4, 2006
Nephros Selects Director William Fox to Serve as Executive Chairman
NEW YORK, July 21, 2006
Nephros Receives Non-compliance Notification from AMEX
NEW YORK, May 24, 2006
Nephros to Present at Dutton Associates' ''Recognizing Opportunity'' Health Sciences SmallCap Conference in San Francisco May 31
NEW YORK, January 13, 2006
Nephros Announces First Order from Major U.S. Hospital for Proprietary Water Filtration System
NEW YORK, November 11, 2005
Nephros Reports Third Quarter 2005 Financial Results
NEW YORK, October 19, 2005
Nephros, Inc. to Present at the C.E. Unterberg Towbin Emerging Growth Life Sciences Conference on October 26th
NEW YORK, August 15, 2005
Nephros Reports Second Quarter 2005 Financial Results
NEW YORK, July 8, 2005
Nephros, Inc. to Receive U.S. Patent for OLpūr™ H2H™
NEW YORK, June 17, 2005
Nephros Receives FDA Approval for its OLpūr™ HD190 High Flux Filter
NEW YORK, June 1, 2005
Nephros, Inc. Presenting at International Renal Conferences
NEW YORK, May 16, 2005
Nephros Reports First Quarter 2005 Financial Results
NEW YORK, April 26, 2005
Nephros Inc. Appoints Bernard Salick, M.D. To Board of Directors
NEW YORK, March 31, 2005
Nephros Reports Fourth Quarter and Year End Financial Results
NEW YORK, March 14, 2005
Nephros Announces 510(K) Filing with FDA for its OLpurT HD190 High Flux Filter
NEW YORK, March 2, 2005
Nephros Enters into Hemodiafilter Manufacturing and Distribution Rights Agreement with Asahi Kasei Medical
NEW YORK, December 23, 2004
Nephros Appoints Deloitte & Touche as Independent Registered Accounting Firm
NEW YORK, November 16, 2004
Nephros, Inc. Reports Third Quarter 2004 Financial Results
NEW YORK, November 11, 2004
Nephros, Inc. Announces Preliminary Evaluation Results for it's
OLp
r™ MD190 Hemodiafilters at Dialysis Center in France
NEW YORK, September 22, 2004
Nephros, Inc. Announces Pricing of Initial Public Offering of it's Common Stock
NEW YORK, October 14, 2003
Nephros, Inc. Receives CE Mark Approval for the OLpr™ MD 190
